SOLO-2 (ENGOT-GCIG/AstraZeneca)

Trial Description: 
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Recurrent Ovarian
Trial Status: 
Completed
Contact person: